The global COVID-19 pandemic has had a significant impact on cancer research and cancer care. While the international community scrambled to identify potential therapies and develop vaccines, a growing and chaotic cacophony of research data was being produced and published, some with very little scientific validation. This meant that misinformation became rife, and some clinical trials were started without clear mechanistic rationale; meanwhile, valuable research and insights were being missed as they were obscured in the chaos. There was a clear need for an objective, data-driven resource to inform and support the coronavirus drug discovery effort. Due to its comprehensive nature, we were able to rapidly develop a coronavirus edition of canSAR (coronacansar.ac.ac.uk) to help support and inform drug discovery and experimental validation for all coronaviruses. A separate publication preprint describing corona canSAR is available (36).
